2025-04-09 – Press Releases – www.prnewswire.com
YANTAI, China, April 9, 2025 /PRNewswire/ — On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented…
